{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:04:54Z","timestamp":1790597094602,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Icteric hepatocellular carcinoma (HCC) is characterized by obstructive jaundice, impaired liver function, and limited treatment options. Biliary drainage may relieve jaundice and permit subsequent anticancer therapy, but the clinical benefit of systemic treatment remains uncertain in this setting. Methods: This retrospective, single-center cohort study included 78 patients with icteric HCC who underwent biliary drainage via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangial drainage (PTCD). Thirty patients received systemic treatment during the treatment course surrounding biliary drainage (five initiated treatment before drainage and 25 on or after drainage), whereas 48 did not receive systemic treatment. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan\u2013Meier analysis and Cox regression. Propensity score matching (PSM), time-dependent Cox regression, and a 42-day landmark analysis were performed as sensitivity analyses. Results: Median OS was longer with systemic treatment than without systemic treatment (14.6 vs. 6.7 months; p = 0.025), as was PFS (7.5 vs. 3.5 months; p = 0.005). After 1:1 PSM, systemic therapy remained associated with longer PFS (7.6 vs. 4.6 months; p = 0.044), whereas the OS difference was not statistically significant. In time-dependent analyses, systemic treatment was not significantly associated with OS (HR, 0.70; 95% CI, 0.40\u20131.22; p = 0.207) or PFS (HR, 0.65; 95% CI, 0.38\u20131.13; p = 0.128). Conclusions: Systemic treatment was associated with favorable outcomes in selected patients in the primary analyses, but these associations were attenuated after accounting for treatment timing. The findings are exploratory and do not establish a causal treatment effect.<\/jats:p>","DOI":"10.3390\/cancers18193138","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:35:59Z","timestamp":1790595359000},"page":"3138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Treatment Versus No Systemic Treatment After Biliary Drainage in Patients with Icteric Hepatocellular Carcinoma: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-1232","authenticated-orcid":false,"given":"Chung-Wei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-8010","authenticated-orcid":false,"given":"Chi-Huan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Yung-Kuan","family":"Tsou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Mu-Hsien","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Kai-Feng","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Cheng-Hui","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on Addressing the Global Hepatocellular Carcinoma Burden: Comprehensive Strategies from Prevention to Treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"ref_2","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e7419","DOI":"10.1002\/cam4.7419","article-title":"DEB-TACE versus cTACE for Unresectable HCC with B1-Type Bile Duct Invasion after Successful Biliary Drainage: A Propensity Score Matching Analysis","volume":"13","author":"Fan","year":"2024","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Woo, H.Y., Han, S.Y., Heo, J., Kim, D.U., Baek, D.H., Yoo, S.Y., Kim, C.W., Kim, S., Song, G.A., and Cho, M. (2017). Role of Endoscopic Biliary Drainage in Advanced Hepatocellular Carcinoma with Jaundice. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187469"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Matsumi, A., Kato, H., Ueki, T., Ishida, E., Takatani, M., Fujii, M., Wato, M., Toyokawa, T., Harada, R., and Tsugeno, H. (2021). Effectiveness, Safety, and Factors Associated with the Clinical Success of Endoscopic Biliary Drainage for Patients with Hepatocellular Carcinoma: A Retrospective Multicenter Study. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-020-01594-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.3748\/wjg.v20.i22.6968","article-title":"Evaluation of Endoscopic Biliary Stenting for Obstructive Jaundice Caused by Hepatocellular Carcinoma","volume":"20","author":"Sugiyama","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.acra.2022.08.010","article-title":"Effect of Biliary Tract Invasion with Obstructive Jaundice on the Prognosis of Patients with Unresectable Hepatocellular Carcinoma","volume":"30","author":"Jiang","year":"2023","journal-title":"Acad. Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC Strategy for Prognosis Prediction and Treatment Recommendations: The 2026 Update","volume":"84","author":"Reig","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000537686","article-title":"Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan","volume":"13","author":"Teng","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","article-title":"AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma","volume":"162","author":"Su","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.5009\/gnl240032","article-title":"Effect of Biliary Drainage on the Prognosis of Patients with Hepatocellular Carcinoma and Bile Duct Invasion","volume":"18","author":"Yang","year":"2024","journal-title":"Gut Liver"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s005350170125","article-title":"Effectiveness of Endoscopic Biliary Drainage for Unresectable Hepatocellular Carcinoma Associated with Obstructive Jaundice","volume":"36","author":"Matsueda","year":"2001","journal-title":"J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_15","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus Rivoceranib versus Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): A Randomised, Open-Label, International Phase 3 Study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (CheckMate 9DW): An Open-Label, Randomised, Phase 3 Trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet Lond. Engl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_23","first-page":"90","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE\u2014Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermosifiliogr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jhbp.512","article-title":"Tokyo Guidelines 2018: Diagnostic Criteria and Severity Grading of Acute Cholangitis (with Videos)","volume":"25","author":"Kiriyama","year":"2018","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The Central Role of the Propensity Score in Observational Studies for Causal Effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000507051","article-title":"Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion","volume":"98","author":"Tanaka","year":"2020","journal-title":"Oncology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Choi, W.-M., Lee, D., Shim, J.H., Kim, K.M., Lim, Y.-S., Lee, H.C., Yoo, C., Park, S.R., Ryu, M.-H., and Ryoo, B.-Y. (2020). Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers, 12.","DOI":"10.3390\/cancers12071968"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1007\/s00432-023-04678-2","article-title":"Survival Outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib in Child Pugh B Unresectable Hepatocellular Carcinoma Patients","volume":"149","author":"Rimini","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17588359221148541","DOI":"10.1177\/17588359221148541","article-title":"Atezolizumab plus Bevacizumab in Patients with Child-Pugh B Advanced Hepatocellular Carcinoma","volume":"15","author":"Cheon","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.5009\/gnl13370","article-title":"Effective Biliary Drainage and Proper Treatment Improve Outcomes of Hepatocellular Carcinoma with Obstructive Jaundice","volume":"8","author":"Suh","year":"2014","journal-title":"Gut Liver"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lee, C.H., Chen, A.H., Hung, S.P., Hsieh, C.E., Tseng, J.H., Chen, P.J., Cheng, J.Y., Chang, J.T., Chan, K.M., and Lin, S.M. (2022). Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Cancers, 14.","DOI":"10.3390\/cancers14071616"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Approach-the ALBI Grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:54:49Z","timestamp":1790596489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":33,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193138"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193138","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}